Kihealth Investor Portal
The molecular intelligence platform for earlier disease interception.
Kihealth is building proprietary blood-based diagnostics designed to reveal active disease biology before conventional clinical measures fully catch up.
Use this private portal to explore the investor presentation, review supporting materials, and access diligence resources.
What Kihealth does
From Biological Signal to Clinical Intelligence
Kihealth combines organ-specific cell-free DNA signals with complementary biomarkers to characterize active cellular injury, track biological change, and generate intelligence that can inform clinical and therapeutic decision-making.
- Biological Signal
- Molecular Intelligence
- Clinical Application
Earlier Disease Detection
Identify molecular evidence of cellular injury before conventional clinical presentation.
Patient Stratification & Monitoring
Characterize disease activity, track biological change, and support more informed patient management.
Therapeutic & Clinical Development
Generate biological insights for patient selection, treatment monitoring, and clinical development.
The Investment Opportunity
A Trillion-Dollar Disease Burden.
A New Diagnostic Layer.
Diabetes affects hundreds of millions of people, yet much of the disease remains undetected or is managed only after meaningful biological change has occurred. Kihealth is building a scalable molecular-intelligence platform designed to support earlier detection, longitudinal monitoring, precision therapeutics, and clinical development across Type 1 and Type 2 diabetes.
Global GLP-1 Market
Annual worldwide sales, USD billions
2024 – 2030
2024 actual
$53B
2030 projected
$139B
Implied growth
2.6×
Source: TD Securities, “GLP-1 Market: The Pipeline Expands.” Diabetes prevalence rises from 589M today to 853M by 2050 (IDF Diabetes Atlas, 11th Edition).
Global Market Context
adults with diabetes; projected to reach 853 million
by 2050.
adults with diabetes are unaware they have the condition.
in annual global diabetes-related health expenditure.
Source: International Diabetes Federation Diabetes Atlas, 11th Edition, 2025
Commercial Value Drivers
Scalable Clinical Diagnostics
Earlier screening and biological risk assessment across large Type 1, prediabetes, and Type 2 populations.
Recurring Longitudinal Monitoring
Repeat testing to follow beta-cell injury, disease progression, and biological response to GLP-1–based and other interventions.
High-Value Biopharma Partnerships
Patient stratification, clinical-trial enrichment, biomarker development, therapeutic monitoring, and complementary biological endpoints.
Kihealth sits at the intersection of molecular diagnostics, precision medicine, diabetes therapeutics, and clinical development, creating the potential for meaningful healthcare impact and multiple recurring, high-value revenue streams.
Explore Kihealth
Start Your Review
Explore the investment opportunity, review supporting materials, access confidential diligence, or connect directly with the Kihealth team.
Request access to Kihealth investor materials.
Submissions are reviewed individually. Access is granted only after administrative approval and, where required, execution of a confidentiality agreement.
Investor relations
Contact the IR teamInvestor access
Investors seeking access to Kihealth investor resources or the confidential Data Room can submit a request below. The Data Room requires a signed NDA.
Go deeper
Explore the Kihealth corporate site.
For additional clarity beyond this portal, kihealthlabs.com covers the science, partnerships, news and press releases, and the clinical program in depth.
Technology applications
In-depth detail on how the molecular-intelligence platform is applied across disease areas.
Scientific validation dashboard
Live view of analytical and clinical validation data supporting the platform.
Ongoing clinical research
Active studies, collaborators, and enrolment progress across the clinical program.
Pipeline development and timing
Assay pipeline stages, expected readouts, and development milestones.